eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
3/2007
vol. 2
 
Share:
Share:
more
 
 
abstract:

Review paper
Impaired glucose tolerance in patients with pancreatic cancer

Anita Gąsiorowska
,
Ewa Małecka-Panas

Przegląd Gastroenterologiczny 2007; 2 (3): 130–134
Online publish date: 2007/07/17
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Pancreatic cancer is the fifth leading cause of cancer death in western countries. It is almost uniformly fatal with dismal 6-month survival from diagnosis. Diabetes or impaired glucose tolerance occurs in up to 60-81% of patients with pancreatic adenocarcinoma. The reason for the frequency with which diabetes is associated with pancreatic cancer is controversial. Diabetes was previously thought to be a predisposing factor for the disease. Recent investigations indicate that diabetes or impaired glucose tolerance is a consequence of pancreatic cancer rather than a predisposing factor for its development. The diabetic state in patients with pancreatic cancer is characterized by high plasma levels of insulin and by reduced body insulin sensitivity. In addition, plasma concentrations of several other pancreatic peptides, such as islet amyloid polypeptide, glucagon and somatostatin, are increased. The decrease in the glucose metabolic rate in patients with pancreatic cancer demonstrated a state of peripheral insulin resistance, which was more severe in diabetic patients than in nondiabetic patients. Some authors have suggested that pancreatic cancer may produce a specific factor that is important in the development of diabetes. A possibility for decreasing mortality from pancreatic cancer is the application of screening and treatment for early pancreatic cancers in patients with new-onset diabetes with invasive and non-invasive imaging tests.
keywords:

pancreatic cancer, diabetes, impaired glucose tolerance, amylin

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe